SILVER SPRING
Saphnelo Pen cleared for SLE self-administration
- Sponsor
- AstraZeneca $AZN
- Drug
- Saphnelo · anifrolumab
- Indication
- systemic lupus erythematosus
FDA approved AstraZeneca's Saphnelo Pen autoinjector for once-weekly subcutaneous self-administration in adult SLE patients.
What this means
Saphnelo is an antibody treatment for lupus that works by blocking certain immune system proteins called interferons, which can drive inflammation. Today FDA cleared a new pen device that lets patients give themselves weekly Saphnelo injections at home instead of needing clinic visits. This change could make treatment more convenient for people with lupus, potentially helping them stick to their medication schedule better.
Drug Watch — recent news on Saphnelo
- Serious Infections Lower With Anifrolumab in CLE Patients - Medscape
- Carving Out a Role for Anifrolumab in Chronic Cutaneous Lupus Erythematosus - The Dermatology Digest
- Immune drug anifrolumab linked to lower risk of infection and hospitalization for skin lupus - Medical Xpress
- Immune Drug Anifrolumab Linked to Lower Risk of Infection and Hospitalization for Skin Lupus - Johns Hopkins Medicine
- Anifrolumab Linked to Lower Cardiovascular Risk Than Belimumab in SLE - Medscape
Sponsor Watch — recent news on AstraZeneca
- Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
- AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success
- AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed
- FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
- Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)